Qiagen NV logo

QGEN - Qiagen NV Share Price

$43.79 0.4  0.8%

Last Trade - 29/05/20

Sector
Healthcare
Size
Large Cap
Market Cap £8.09bn
Enterprise Value £8.88bn
Revenue £1.26bn
Position in Universe 709th / 6364
Bullish
Bearish
Unlock QGEN Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Qiagen NV revenues increased 7% to $372.1M. Net income increased 35% to $39.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Intangible Amortization decrease of 45% to $5.1M (expense), Interest expense decrease of 7% to $18.9M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

QGEN Revenue Unlock QGEN Revenue

Net Income

QGEN Net Income Unlock QGEN Revenue

Normalised EPS

QGEN Normalised EPS Unlock QGEN Revenue

PE Ratio Range

QGEN PE Ratio Range Unlock QGEN Revenue

Dividend Yield Range

QGEN Dividend Yield Range Unlock QGEN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
QGEN EPS Forecasts Unlock QGEN Revenue
Profile Summary

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated April 29, 1996
Public Since September 1, 1996
No. of Shareholders: 106
No. of Employees: 5,096
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange New York Stock Exchange
Shares in Issue 228,163,000
Free Float (0.0%)
Eligible for
ISAs
SIPPs
QGEN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for QGEN
Upcoming Events for QGEN
Frequently Asked Questions for Qiagen NV
What is the Qiagen NV share price?

As of 29/05/20, shares in Qiagen NV are trading at $43.79, giving the company a market capitalisation of £8.09bn. This share price information is delayed by 15 minutes.

How has the Qiagen NV share price performed this year?

Shares in Qiagen NV are currently trading at $43.79 and the price has moved by 15.63% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Qiagen NV price has moved by 5.03% over the past year.

What are the analyst and broker recommendations for Qiagen NV?

Of the analysts with advisory recommendations for Qiagen NV, there are there are currently 1 "buy" , 8 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Qiagen NV is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Qiagen NV next release its financial results?

Qiagen NV is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Qiagen NV dividend yield?

Qiagen NV does not currently pay a dividend.

Does Qiagen NV pay a dividend?

Qiagen NV does not currently pay a dividend.

When does Qiagen NV next pay dividends?

Qiagen NV does not currently pay a dividend.

How do I buy Qiagen NV shares?

To buy shares in Qiagen NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Qiagen NV?

Shares in Qiagen NV are currently trading at $43.79, giving the company a market capitalisation of £8.09bn.

Where are Qiagen NV shares listed? Where are Qiagen NV shares listed?

Here are the trading details for Qiagen NV:

Country of listing: United States
Exchange: NYQ
Ticker Symbol: QGEN
What kind of share is Qiagen NV?

Based on an overall assessment of its quality, value and momentum, Qiagen NV is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Qiagen NV share price forecast 2020?

Shares in Qiagen NV are currently priced at $43.79. At that level they are trading at 13.91% premium to the analyst consensus target price of 0.00.

Analysts covering Qiagen NV currently have a consensus Earnings Per Share (EPS) forecast of 1.494 for the next financial year.

How can I tell whether the Qiagen NV share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Qiagen NV. Over the past six months, the relative strength of its shares against the market has been 5.15%. At the current price of $43.79, shares in Qiagen NV are trading at 19.05% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Qiagen NV PE Ratio?

The Qiagen NV PE ratio based on its reported earnings over the past 12 months is 52.17. The shares are currently trading at $43.79.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Qiagen NV?

Qiagen NV's management team is headed by:

Roland Sackers - CFO
Hakan Bjorklund - CSU
Thierry Bernard - CEO
Metin Colpan - IND
Elaine Mardis - IND
Stephane Bancel - IND
Ross Levine - IND
Lawrence Rosen - IND
Who are the major shareholders of Qiagen NV?

Here are the top five shareholders of Qiagen NV based on the size of their shareholding:

Amundi Asset Management Investment Advisor/Hedge Fund
Percentage owned: 11.52% (26.6m shares)
PRIMECAP Management Company Investment Advisor
Percentage owned: 6.21% (14.3m shares)
Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 5.22% (12.0m shares)
MFS Investment Management Investment Advisor/Hedge Fund
Percentage owned: 4.67% (10.8m shares)
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund
Percentage owned: 3.38% (7.80m shares)
Similar to QGEN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.